言語を選択

CD52

CD52 詳細

英語名	CAMPATH-1 antigen	市販薬剤の数	1
治験薬の数	5	ターゲットの別称	Epididymis Secretory Sperm Binding Protein Li 171mP，CD52 Antigen (CAMPATH-1 Antigen)，Epididymal Secretory Protein E5，He5，CDW52 Antigen (CAMPATH-1 Antigen)，CD52 Antigen，HEL-S-171mP，EDDM5，CD52，CDw52，Cambridge pathology 1 antigen，Human epididymis-specific protein 5，CAMPATH-1 antigen，CD52 Molecule
研究＆開発段階	Approved

英語名	CAMPATH-1 antigen
ターゲットの別称	Epididymis Secretory Sperm Binding Protein Li 171mP，CD52 Antigen (CAMPATH-1 Antigen)，Epididymal Secretory Protein E5，He5，CDW52 Antigen (CAMPATH-1 Antigen)，CD52 Antigen，HEL-S-171mP，EDDM5，CD52，CDw52，Cambridge pathology 1 antigen，Human epididymis-specific protein 5，CAMPATH-1 antigen，CD52 Molecule
市販薬剤の数	1
治験薬の数	5
研究＆開発段階	Approved

CD52 製品リスト

属性
Protein (3)Antibody (2)
製品ライブラリ
オンライン (5)
種
Human (5)
タグ
Fc Tag & Avi Tag (1)Fc Tag (1)His Tag & Avi Tag (1)- (2)
マーカー
Biotin-labeled (2)Unconjugated (3)

製品番号	種	発現システム	製品説明
HOT CD2-H82E8	Human	HEK293	Biotinylated Human CD52 Protein, His,Avitag™
CD2-C263G1	Human	HEK293	Monoclonal Anti-CD52 Antibody, Human IgG1, premium grade
CD2-C263GN	Human	HEK293	Monoclonal Anti-CD52 Antibody, Human IgG1, Research Grade
CD2-H525a	Human	HEK293	Human CD52 Protein, Fc Tag
CD2-H82F3	Human	HEK293	Biotinylated Human CD52 Protein, Fc,Avitag™

総数量5

CD52バックグランド

CAMPATH-1 antigen, also known as cluster of differentiation 52 (CD52), is a glycoprotein that in humans is encoded by the CD52 gene.It is widely expressed on the cell surface of immune cells, such as mature lymphocytes, natural killer cells (NK), eosinophils, neutrophils, monocytes/macrophages, and dendritic cells (DCs).ligation of cell surface CD52 molecules may offer costimulatory signals for T-cell activation and proliferation.

CD52分子の別称

CDW52,HE5,CD52,CAMPATH-1 antigen

治験薬に関する情報

英語名	研究コード	研究開発ステージ	会社	適応症	臨床試験
Alemtuzumab biosimilar (Zhangjiang Biotechnology)		Phase 2 Clinical	Shanghai Zhangjiang Biotechnology Co Ltd	Leukemia, Lymphocytic, Chronic, B-Cell	詳細
ALLO-647	ALLO-647	Phase 2 Clinical	Allogene Therapeutics Inc	Carcinoma, Renal Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Multiple Myeloma	詳細
Alemtuzumab Biosimilars(Cellectis)	CLLS-52; CLLS52	Phase 2 Clinical	Cellectis Sa	Leukemia, Myeloid, Acute; Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma	詳細
Recombinant anti-CD52 humanized monoclonal antibody (Lanzhou Institute Of Biological Products/Shanghai Taiyin Biotechnology)		Phase 1 Clinical	Lanzhou Institute Of Biological Products Co Ltd, Shanghai Taiyin Biotechnology Co Ltd	Leukemia, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic; Leukemia, Prolymphocytic, T-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell	詳細
Alemtuzumab biosimilar(BioXpress)	BX-1523; BXT-1523	Clinical	Bioxpress Therapeutics Sa	Leukemia, B-Cell; Multiple Sclerosis	詳細

市販薬剤に関する情報

英語名	研究コード	研究開発ステージ	会社	オリジナル製品名	最初に承認をした国	最初の適応症	最初に承認を受けた会社	承認された日付	適応症	臨床試験
Alemtuzumab	LDP-03; GZ-402673	Approved	Bayer AG, Genzyme Corp	Campath, Lemtrada, MabCampath	United States	Multiple Sclerosis	Genzyme Corp	2001-05-07	Anemia, Aplastic; Anemia, Sickle Cell; Bone marrow transplant rejection; Diabetes Mellitus, Type 1; Fallopian Tube Neoplasms; Graft Rejection; Graft vs Host Disease; Hematologic Neoplasms; Hodgkin Disease; Kidney Diseases; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Leukemia, Prolymphocytic, T-Cell; Leukemia, T-Cell; Leukemia-Lymphoma, Adult T-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Lymphoproliferative Disorders; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Mycosis Fungoides; Myelodysplastic Syndromes; Myositis, Inclusion Body; Ovarian Neoplasms; Pancytopenia; Peritoneal Neoplasms; Rejection of renal transplantation; Sezary Syndrome; Waldenstrom Macroglobulinemia	詳細